ArticleScientific reports2025
Integrated single cell and bulk RNA sequencing analyses reveal the impact of tryptophan metabolism on prognosis and immunotherapy in colon cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth.Cell reports. Medicine · 2026Article
- Identification of RNA processing-related gene-based bladder cancer subtypes for prognosis and immune landscape assessment.Translational andrology and urology · 2026Article
- Investigating tryptophan metabolism in colorectal cancer using Single-cell RNA sequencing based on machine learning techniques.PloS one · 2026Article
- Molecular mechanisms and clinical significance of the glioma metabolic-immune axis: a comprehensive review.Frontiers in immunology · 2026Review
- A mitochondrial lipid metabolism-related gene signature predicts prognosis and immune landscape in colorectal cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Tryptophan metabolism is intricately associated with the progression of colon cancer. This research endeavored to meticulously analyze tryptophan metabolic characteristics in colon cancer and forecast immunotherapy responses. This study analyzed colon cancer samples from a training cohort of 473 tumors and 41 normal tissues from TCGA, with validation in 902 cancer patients across multiple GEO datasets. Patients were stratified into subtypes through consistent clustering, and a tryptophan metabolic risk score model was constructed using the random forest algorithm. Based on these risk scores, patients were delineated into high and low-risk groups, and their clinicopathologic characteristics, immune cell infiltration, immune checkpoint expression, and signaling pathway disparities were examined. The Oncopredict algorithm facilitated the identification of sensitive chemotherapeutic agents, while the immune escape score was employed to evaluate the immunotherapy response across risk groups. Transcriptomic sequencing findings were corroborated by single-cell sequencing from Shanghai Ruijin Hospital. Two distinct subtypes of colon cancer patients emerged, exhibiting significant prognostic and immune cell infiltration differences. The high-risk group demonstrated a poorer prognosis (p < 0.001), advanced clinical stage (p < 0.001), and elevated immunosuppressive cell expression (p < 0.05). Additionally, three chemotherapeutic drugs showed efficacy in the high-risk cohort, displaying a heightened immune escape potential (p < 0.05) and diminished response to immunotherapy. Single-cell sequencing validated the overexpression of tryptophan-related genes in epithelial cells. In conclusion, tryptophan metabolism significantly influences the colon cancer immune microenvironment, with high-risk patients experiencing adverse prognoses and potentially reduced efficacy of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.